Cue Biopharma downsizes to focus on autoimmune pipeline
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce…
Cue Biopharma has instituted strategic restructuring measures with a plan to focus on autoimmune programmes and carry out a workforce…
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day…
AstraZeneca has signed a licensing agreement with Pinetree Therapeutics for a preclinical epidermal growth factor receptor (EGFR) degrader candidate, potentially…
Johnson and Johnson (J&J) Innovative Medicine has decided to halt the development of its epilepsy drug, three months after a…
The US Department of Health and Human Services (HHS) has exercised a procurement option for SIGA Technologies’ oral Tpoxx (tecovirimat).…
Exscientia has taken full ownership of an oral cyclin-dependent kinase 7 (CDK7) inhibitor after buying out its development partner GT…
Bayer is set to pursue a label expansion for Nubeqa (darolutamide) in a distinct subgroup of prostate cancer patients—those with…
US-based cardiology biotech Cardurion Pharmaceuticals has raised $260m in Series B financing to advance its drug pipeline. The proceeds will…
Since its introduction in January, the BIOSECURE Act has sent shockwaves across the pharmaceutical sector. Although the Act does not…
SOTIO Biotech has signed a research and licensing agreement with China-based Biocytogen to develop multiple bispecific antibody-drug conjugate (ADC) candidates…